XYLOCAINE W Drug Patent Profile
✉ Email this page to a colleague
When do Xylocaine W patents expire, and when can generic versions of Xylocaine W launch?
Xylocaine W is a drug marketed by Astrazeneca and Fresenius Kabi Usa and is included in two NDAs.
The generic ingredient in XYLOCAINE W is epinephrine; lidocaine hydrochloride. There are twenty-one drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the epinephrine; lidocaine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XYLOCAINE W?
- What are the global sales for XYLOCAINE W?
- What is Average Wholesale Price for XYLOCAINE W?
Summary for XYLOCAINE W
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| DailyMed Link: | XYLOCAINE W at DailyMed |
US Patents and Regulatory Information for XYLOCAINE W
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | XYLOCAINE W/ EPINEPHRINE | epinephrine; lidocaine hydrochloride | INJECTABLE;INJECTION | 010418-006 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Kabi Usa | XYLOCAINE W/ EPINEPHRINE | epinephrine; lidocaine hydrochloride | INJECTABLE;INJECTION | 006488-019 | Nov 13, 1986 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Fresenius Kabi Usa | XYLOCAINE W/ EPINEPHRINE | epinephrine; lidocaine hydrochloride | INJECTABLE;INJECTION | 006488-012 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
